Zirabev FDA Approval History
FDA Approved: Yes (First approved June 27, 2019)
Brand name: Zirabev
Generic name: bevacizumab-bvzr
Dosage form: Injection
Company: Pfizer Inc.
Treatment for: Colorectal Cancer, Non Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Last updated by Judith Stewart, BPharm on April 10, 2022.
Zirabev (bevacizumab-bvzr) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Zirabev (bevacizumab-bvzr) is the the second FDA-approved bevacizumab biosimilar, following the approval of Mvasi (bevacizumab-awwb) in September 2017.
Development timeline for Zirabev
Date | Article |
---|---|
Jun 28, 2019 | Approval FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.